The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...
Because it is still awaiting approval, Medicare does not typically cover the use of ketamine infusion for treating mental ...
"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...
Hosted on MSN7d
FDA approves Spravato, nasal spray derived from KetamineThe FDA approves Spravato, a nasal spray derived from Ketamine, to help some people treat depression. Dr. Bill Hartman from UW Health shares more.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback